# Andrew Wardley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrew-wardley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,142 |
| Field | Breast Cancer Treatment Studies |
| h-index | 54 |
| i10-index | 111 |
| Last Known Institution | UK Research and Innovation |
| OpenAlex ID | https://openalex.org/A5065272343 |
| ORCID iD | https://orcid.org/0000-0002-9639-0888 |
| Works | 324 |

## Researcher papers

- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
- [Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study](https://scholariq.org/papers/adjuvant-abemaciclib-combined-with-endocrine-therapy-for-high-risk-early-breast/)
- [Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/abemaciclib-plus-trastuzumab-with-or-without-fulvestrant-versus-trastuzumab-plus/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [UK Research and Innovation](https://scholariq.org/institutions/uk-research-and-innovation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.